Nutritional Intervention to Prevent (NIP) Type 1 Diabetes A Pilot Trial

H. Peter Chase, Ellen Lescheck, Lisa Rafkin, Heidi Krause-Steinrauf, Sonia Chritton, Smita M. Asare, Sara Adams, Jay S Skyler, Michael Clare-Salzler

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The objective of this study was to describe a pilot trial of using an omega-3 fatty acid (docosahexaenoic acid [DHA]) to prevent islet cell autoimmunity in infants with an increased risk for developing type 1 diabetes (T1D). Infants from pregnant mothers who either have T1D (or the father or a previous child has T1D) and who entered the study in the third trimester or infants younger than age 5 months having a first-degree family member with T1D were eligible for the study. Infants from either group also had to have an increased genetic (HLA) risk for T1D (or multiple first-degree relatives with T1D) to be eligible. The study is a multicenter, 2-arm, randomized, double-masked clinical trial that will last 4 years (1 year of recruitment and 3 years of treatment). Treatment with DHA (or control) began in the last trimester of pregnancy or in the first 5 months after birth. Inflammatory mediators, including cytokines, chemokines, eicosanoids, and C-reactive protein, are being measured along with fatty acids in maternal and infant blood. Ninety-eight infants were enrolled (41 during pregnancy and 57 in the 5 months after birth). HLA results of the 97 eligible infants (1 infant had a protective 0602 allele and was thus ineligible) showed that 90 have DR3 and/or DR4. Seven infants were enrolled without DR3/4 but who instead had multiple first-degree relatives with T1D. Compliance has been excellent, and no families have discontinued participation. Intervention trials in this high-risk group are feasible but require significant effort to identify potential participants.

Original languageEnglish (US)
Pages (from-to)98-107
Number of pages10
JournalInfant, Child, and Adolescent Nutrition
Volume1
Issue number2
DOIs
StatePublished - 2009

Fingerprint

nutritional intervention
insulin-dependent diabetes mellitus
Type 1 Diabetes Mellitus
docosahexaenoic acid
Docosahexaenoic Acids
Third Pregnancy Trimester
pregnancy
autoimmunity
eicosanoids
risk groups
Mothers
Parturition
C-reactive protein
islets of Langerhans
fathers
chemokines
Pregnancy
omega-3 fatty acids
compliance
Eicosanoids

Keywords

  • chronic disease management
  • diabetes (type 1 and 2)
  • nutritional intervention
  • prevent type 1

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Food Science
  • Nutrition and Dietetics

Cite this

Chase, H. P., Lescheck, E., Rafkin, L., Krause-Steinrauf, H., Chritton, S., Asare, S. M., ... Clare-Salzler, M. (2009). Nutritional Intervention to Prevent (NIP) Type 1 Diabetes A Pilot Trial. Infant, Child, and Adolescent Nutrition, 1(2), 98-107. https://doi.org/10.1177/1941406409333466

Nutritional Intervention to Prevent (NIP) Type 1 Diabetes A Pilot Trial. / Chase, H. Peter; Lescheck, Ellen; Rafkin, Lisa; Krause-Steinrauf, Heidi; Chritton, Sonia; Asare, Smita M.; Adams, Sara; Skyler, Jay S; Clare-Salzler, Michael.

In: Infant, Child, and Adolescent Nutrition, Vol. 1, No. 2, 2009, p. 98-107.

Research output: Contribution to journalArticle

Chase, HP, Lescheck, E, Rafkin, L, Krause-Steinrauf, H, Chritton, S, Asare, SM, Adams, S, Skyler, JS & Clare-Salzler, M 2009, 'Nutritional Intervention to Prevent (NIP) Type 1 Diabetes A Pilot Trial', Infant, Child, and Adolescent Nutrition, vol. 1, no. 2, pp. 98-107. https://doi.org/10.1177/1941406409333466
Chase, H. Peter ; Lescheck, Ellen ; Rafkin, Lisa ; Krause-Steinrauf, Heidi ; Chritton, Sonia ; Asare, Smita M. ; Adams, Sara ; Skyler, Jay S ; Clare-Salzler, Michael. / Nutritional Intervention to Prevent (NIP) Type 1 Diabetes A Pilot Trial. In: Infant, Child, and Adolescent Nutrition. 2009 ; Vol. 1, No. 2. pp. 98-107.
@article{71410d0782a74e4d89571df7962480aa,
title = "Nutritional Intervention to Prevent (NIP) Type 1 Diabetes A Pilot Trial",
abstract = "The objective of this study was to describe a pilot trial of using an omega-3 fatty acid (docosahexaenoic acid [DHA]) to prevent islet cell autoimmunity in infants with an increased risk for developing type 1 diabetes (T1D). Infants from pregnant mothers who either have T1D (or the father or a previous child has T1D) and who entered the study in the third trimester or infants younger than age 5 months having a first-degree family member with T1D were eligible for the study. Infants from either group also had to have an increased genetic (HLA) risk for T1D (or multiple first-degree relatives with T1D) to be eligible. The study is a multicenter, 2-arm, randomized, double-masked clinical trial that will last 4 years (1 year of recruitment and 3 years of treatment). Treatment with DHA (or control) began in the last trimester of pregnancy or in the first 5 months after birth. Inflammatory mediators, including cytokines, chemokines, eicosanoids, and C-reactive protein, are being measured along with fatty acids in maternal and infant blood. Ninety-eight infants were enrolled (41 during pregnancy and 57 in the 5 months after birth). HLA results of the 97 eligible infants (1 infant had a protective 0602 allele and was thus ineligible) showed that 90 have DR3 and/or DR4. Seven infants were enrolled without DR3/4 but who instead had multiple first-degree relatives with T1D. Compliance has been excellent, and no families have discontinued participation. Intervention trials in this high-risk group are feasible but require significant effort to identify potential participants.",
keywords = "chronic disease management, diabetes (type 1 and 2), nutritional intervention, prevent type 1",
author = "Chase, {H. Peter} and Ellen Lescheck and Lisa Rafkin and Heidi Krause-Steinrauf and Sonia Chritton and Asare, {Smita M.} and Sara Adams and Skyler, {Jay S} and Michael Clare-Salzler",
year = "2009",
doi = "10.1177/1941406409333466",
language = "English (US)",
volume = "1",
pages = "98--107",
journal = "Infant, Child, and Adolescent Nutrition",
issn = "1941-4064",
publisher = "Sage Periodicals Press",
number = "2",

}

TY - JOUR

T1 - Nutritional Intervention to Prevent (NIP) Type 1 Diabetes A Pilot Trial

AU - Chase, H. Peter

AU - Lescheck, Ellen

AU - Rafkin, Lisa

AU - Krause-Steinrauf, Heidi

AU - Chritton, Sonia

AU - Asare, Smita M.

AU - Adams, Sara

AU - Skyler, Jay S

AU - Clare-Salzler, Michael

PY - 2009

Y1 - 2009

N2 - The objective of this study was to describe a pilot trial of using an omega-3 fatty acid (docosahexaenoic acid [DHA]) to prevent islet cell autoimmunity in infants with an increased risk for developing type 1 diabetes (T1D). Infants from pregnant mothers who either have T1D (or the father or a previous child has T1D) and who entered the study in the third trimester or infants younger than age 5 months having a first-degree family member with T1D were eligible for the study. Infants from either group also had to have an increased genetic (HLA) risk for T1D (or multiple first-degree relatives with T1D) to be eligible. The study is a multicenter, 2-arm, randomized, double-masked clinical trial that will last 4 years (1 year of recruitment and 3 years of treatment). Treatment with DHA (or control) began in the last trimester of pregnancy or in the first 5 months after birth. Inflammatory mediators, including cytokines, chemokines, eicosanoids, and C-reactive protein, are being measured along with fatty acids in maternal and infant blood. Ninety-eight infants were enrolled (41 during pregnancy and 57 in the 5 months after birth). HLA results of the 97 eligible infants (1 infant had a protective 0602 allele and was thus ineligible) showed that 90 have DR3 and/or DR4. Seven infants were enrolled without DR3/4 but who instead had multiple first-degree relatives with T1D. Compliance has been excellent, and no families have discontinued participation. Intervention trials in this high-risk group are feasible but require significant effort to identify potential participants.

AB - The objective of this study was to describe a pilot trial of using an omega-3 fatty acid (docosahexaenoic acid [DHA]) to prevent islet cell autoimmunity in infants with an increased risk for developing type 1 diabetes (T1D). Infants from pregnant mothers who either have T1D (or the father or a previous child has T1D) and who entered the study in the third trimester or infants younger than age 5 months having a first-degree family member with T1D were eligible for the study. Infants from either group also had to have an increased genetic (HLA) risk for T1D (or multiple first-degree relatives with T1D) to be eligible. The study is a multicenter, 2-arm, randomized, double-masked clinical trial that will last 4 years (1 year of recruitment and 3 years of treatment). Treatment with DHA (or control) began in the last trimester of pregnancy or in the first 5 months after birth. Inflammatory mediators, including cytokines, chemokines, eicosanoids, and C-reactive protein, are being measured along with fatty acids in maternal and infant blood. Ninety-eight infants were enrolled (41 during pregnancy and 57 in the 5 months after birth). HLA results of the 97 eligible infants (1 infant had a protective 0602 allele and was thus ineligible) showed that 90 have DR3 and/or DR4. Seven infants were enrolled without DR3/4 but who instead had multiple first-degree relatives with T1D. Compliance has been excellent, and no families have discontinued participation. Intervention trials in this high-risk group are feasible but require significant effort to identify potential participants.

KW - chronic disease management

KW - diabetes (type 1 and 2)

KW - nutritional intervention

KW - prevent type 1

UR - http://www.scopus.com/inward/record.url?scp=84998146100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84998146100&partnerID=8YFLogxK

U2 - 10.1177/1941406409333466

DO - 10.1177/1941406409333466

M3 - Article

AN - SCOPUS:84998146100

VL - 1

SP - 98

EP - 107

JO - Infant, Child, and Adolescent Nutrition

JF - Infant, Child, and Adolescent Nutrition

SN - 1941-4064

IS - 2

ER -